Pharma & More SRL
23.8 FTEPharma & More reported total assets of €4.43m at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jan 2026), with 23.8 full-time equivalents.
The score of Pharma & More shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +419 % Total assets +218 % Headcount (avg FTE) +177 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma & More's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 31 Jan 2026
- Year ended 30 Jun 2024filed on 31 Jan 2025
- Year ended 30 Jun 2023filed on 31 Jan 2024
- Year ended 30 Jun 2022filed on 31 Jan 2023
Pharma & More's financial analysis
- Solvency30.2%sector median: 33.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma & More
Pharma & More's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0774.831.545
- VAT number
- BE0774831545
- Peppol
- Registered · 0208:0774831545 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 30 Sep 2021
- Registered office
- 9070 Destelbergen
- Size
- Small · 23.8 FTE
- Latest accounts
- 2025 · filed on 31 Jan 2026
- Activity
- Wholesale of perfume and cosmetics (NACE 46450)
Pharma & More (SRL) has been based in Destelbergen since 2021, active in: wholesale of perfume and cosmetics. For 2025, it reports a net profit of 156,367 € and equity of €1.34m; its revenue is not published. With 23.8 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 30.2%, below the median of its sector (33.5%).
Companies similar to Pharma & More
Companies in the same business, of comparable size and area, outside its group.
- Aagato Medical Wholesale of pharmaceutical and medical goods Ghent · balance sheet €3.86m
- LDU Belux Wholesale of perfume and cosmetics Anderlecht · balance sheet €3.07m
- Lupumed Wholesale of pharmaceutical and medical goods Ghent · balance sheet €2.08m
- Emmagenics Wholesale of pharmaceutical and medical goods Ghent · balance sheet 643,095 €
- XPT-Engineering Business and other management consultancy activities Schilde · balance sheet 591,468 €
- Fagron Belgium Wholesale of pharmaceutical and medical goods Nazareth-De Pinte · balance sheet €7.86m
- SBT Lab Wholesale of perfume and cosmetics Aalter · balance sheet €1.76m
- Defrahair Wholesale of perfume and cosmetics Lochristi · balance sheet 229,047 €
Frequently asked questions about Pharma & More
What is the revenue of Pharma & More?
Pharma & More files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma & More?
In Belgium, the VAT number is the company number prefixed with BE: BE0774831545 for Pharma & More, if the company is VAT-registered. Its company number (CBE) is 0774.831.545.
Where is the registered office of Pharma & More?
According to the CBE register, the registered office of Pharma & More is in 9070 Destelbergen.
What is the equity of Pharma & More?
At the close of the 2025 financial year, the equity of Pharma & More amounts to 1,336,405 €, a solvency of 30.2% of total assets.
How many people work at Pharma & More?
23.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharma & More?
The register lists 2 active mandates at Pharma & More. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma & More
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →